Overview


According to FutureWise analysis the market for bio pharma buffer is expected to reach US$ 1.4 billion by 2031 at a CAGR of 7.72%.

Buffers are used in a variety of biopharmaceutical processes such as protein isolation and purification, polishing, filtration, and chromatographic, reaction, and crystallisation steps. Buffers are especially important in downstream processes to protect proteins from pH variations. Buffers protect proteins from pH variations by buffering or absorbing changes in pH. Despite changes in processing, containers, and raw materials, a well-buffered solution will maintain its pH. Proteins are pH sensitive, which can cause denaturation, aggregation, and fragmentation. A weak conjugate acid-base pair composes a buffer solution. When small amounts of other acids or bases are added to the solution, they are neutralised, and the solution resists pH changes. Because protein-based biologic APIs are sensitive to pH changes, solutions with stable pH are required for processing. The conjugate acid-base pair determines a buffer's stable pH range and capacity. A variety of biopharmaceutical process steps require pH control. Therefore, bio pharma buffers are integral part for pharmaceuticals.

An acid-base pair with a weak conjugate bond makes up a buffer solution. The solution resists change in pH because small amounts of other acids or bases are neutralized when added to it. As protein-based biologic APIs are sensitive to pH variations, solutions with constant pH are required for processing them. The conjugate acid-base pair determines the buffer's stable pH range and capacity (the amount of acid or base that may be supplied without changing pH). The bio-pharma buffer market is being driven by the increasing demand for blood and blood plasma for transfusion purposes as well as the ongoing global immunization campaign against illnesses like polio, rubella, and other similar conditions.

FutureWise Market Research has published a report that provides an insightful analysis of bio pharma buffers market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the bio pharma buffers market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

The demand for pharmaceuticals and treatments in developing countries is expected to drive the market for biopharmaceutical buffers. Furthermore, the market will benefit from rising health insurance premiums and healthcare costs. During the forecast period, government and consumer demand for biopharmaceutical buffers will rise. The demand for these goods has expanded as a result of the rising popularity of this sort of treatment, and the biopharma buffer market is predicted to expand substantially in the years to come. The primary factors propelling the growth of this market are the use of cutting-edge and technical manufacturing parameters, rising consumer awareness of effective antioxidants and suggestions for antioxidant supplementation. The bio pharma buffer industry is growing quickly, and businesses are using cutting-edge technology to increase the efficacy of their goods. A wider variety of goods and services are in more demand as the market grows. The main problems with biopharmaceutical goods are their high cost and sluggish manufacture. For many industries, high expenses are the biggest worry since they increase product prices, which harm client bases. This is brought on by escalating costs for raw materials, production procedures, product stability issues, and shelf-life considerations. Given how crucial stability is, any change in it could lower the product's quality and harm the biopharma buffer market.

  • Avantor
  • Alfa Aesar (Thermo Fisher)
  • Merck
  • Lonza
  • Bio-Rad
  • BD
  • GE Healthcare
  • Promega Corporation
  • Hamilton Company
  • XZL BIO-TECHNOLOGY
  • SRL

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Phosphates Type
  • Acetates Type
  • TRIS Type
  • Others

By Application

  • Research Institution
  • Pharmaceutical Industry
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The expansion of the global biopharma buffer ecosystem is mostly due to the rising research activities and the rise in the number of biotech enterprises in this region. Also, a significant end-user of these goods and services in this country has developed as the expanding pharmaceutical industry. According to type, phosphate type occupies 43.1% of the market in 2022, acetate type holds 25.8%, and TRIS holds 12.6%.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Bio Pharma Buffer Market By Type, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Bio Pharma Buffer Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Bio Pharma Buffer Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Bio Pharma Buffer Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Bio Pharma Buffer Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Phosphates Type
        2. Acetates Type
        3. TRIS Type
        4. Others

  • 8.   Bio Pharma Buffer Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Research Institution
        2. Pharmaceutical Industry
        3. Others

  • 9.   North America Bio Pharma Buffer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Bio Pharma Buffer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Bio Pharma Buffer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Bio Pharma Buffer Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Avantor
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Alfa Aesar (Thermo Fisher)
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Merck
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Lonza
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bio-Rad
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. BD
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. GE Healthcare
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Promega Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Hamilton Company
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. XZL BIO-TECHNOLOGY
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. SRL
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients